Evaluation of Fab and F(ab′)2 Fragments and Isotype Variants of a Recombinant Human Monoclonal Antibody against Shiga Toxin 2

被引:19
作者
Akiyoshi, Donna E. [1 ]
Sheoran, Abhineet S. [1 ]
Rich, Curtis M. [1 ]
Richard, L. [1 ]
Chapman-Bonofiglio, Susan [1 ]
Tzipori, Saul [1 ]
机构
[1] Tufts Cummings Sch Vet Med, Dept Biomed Sci, Div Infect Dis, North Grafton, MA 01536 USA
基金
美国国家卫生研究院;
关键词
HEMOLYTIC-UREMIC SYNDROME; ESCHERICHIA-COLI; SYSTEMIC COMPLICATIONS; INFECTIONS; SUBUNIT; MICE; IDENTIFICATION; SHIGA-TOXIN-2; PATHOGENESIS; PROTECTION;
D O I
10.1128/IAI.00867-09
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
5C12 HuMAb is a human monoclonal antibody against the A subunit of Shiga toxin 2 (Stx2). We have previously shown that 5C12 HuMAb effectively neutralizes the cytotoxic effects of this toxin by redirecting its transport within the cell and also by neutralizing the toxin's ability to inhibit protein synthesis. The 5C12 HuMAb and its recombinant IgG1 version protect mice at a dose of 0.6 mu g against a lethal challenge of Stx2. The contribution of the Fc region to this observed neutralization activity of the 5C12 antibody against Stx2 was investigated in this study. Using recombinant DNA technology, 5C12 isotype variants (IgG1, IgG2, IgG3, and IgG4) and antibody fragments [Fab, F(ab')(2)] were expressed in Chinese hamster ovary cells and evaluated in vitro and in vivo. All four 5C12 isotype variants showed protection in vitro, with the IgG3 and IgG4 variants showing the highest protection in vivo. The Fab and F(ab')(2) fragments also showed protection in vitro but no protection in the mouse toxicity model. Similar results were obtained for a second HuMAb (5H8) against the B subunit of Stx2. The data suggest the importance of the Fc region for neutralization activity, but it is not clear if this is related to the stability of the full-length antibody or if the Fc region is required for effective elimination of the toxin from the body.
引用
收藏
页码:1376 / 1382
页数:7
相关论文
共 35 条
[1]   Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells [J].
Akiyoshi, DE ;
Rich, CM ;
O'Sullivan-Murphy, S ;
Richard, L ;
Dilo, J ;
Donohue-Rolfe, A ;
Sheoran, AS ;
Chapman-Bonofiglio, S ;
Tzipori, S .
INFECTION AND IMMUNITY, 2005, 73 (07) :4054-4061
[2]  
Andrew S.M., 2003, CURR PROTOC CELL BIO, V16
[3]   Retrograde transport from endosomes to the trans-Golgi network [J].
Bonifacino, Juan S. ;
Rojas, Raul .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (08) :568-579
[4]   Shiga toxins and apoptosis [J].
Cherla, RP ;
Lee, SY ;
Tesh, VL .
FEMS MICROBIOLOGY LETTERS, 2003, 228 (02) :159-166
[5]  
Edwards A.C., 1998, ESCHERICHIA COLI O15, P388
[6]   Shiga toxin-producing Escherichia coli:: An overview [J].
Gyles, C. L. .
JOURNAL OF ANIMAL SCIENCE, 2007, 85 :E45-E62
[7]   Characterization of a Shiga toxin 1-neutralizing recombinant fab fragment isolated by phage display system [J].
Inoue, K ;
Itoh, K ;
Nakao, H ;
Takeda, T ;
Suzuki, T .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 203 (04) :295-303
[8]  
Kabat EA, 1992, NIH PUBLICATION, V91-3242
[9]   Enterohaemorrhagic Escherichia coli in human medicine [J].
Karch, H ;
Tarr, PI ;
Blelaszewska, M .
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 295 (6-7) :405-418
[10]   Infection by shiga toxin-producing Escherichia coli -: An overview [J].
Karmali, MA .
MOLECULAR BIOTECHNOLOGY, 2004, 26 (02) :117-122